Calcitonin Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: March 06, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
4.1% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Indications, Route of Administration, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global calcitonin treatment market is expected to register a revenue CAGR of 4.1% by 2031.
Calcitonin Treatment Market Fundamentals
Calcitonin, also known as thyrocalcitonin, is a linear polypeptide hormone produced by parafollicular cells in the thyroid glands of humans. Calcitonin is generated by cells of the ultimobranchial body in birds, fish, and other non-mammalian animals. Calcitonin decreases calcium and phosphate levels in the blood and stimulates bone growth. The hormone inhibits bone removal cells, known as osteoclasts, while simultaneously promoting bone-building cells, known as osteoblasts.
Salmon calcitonin is considered an analog to human calcitonin. Salmon calcitonin is mostly preferred in treating bone-related diseases, such as Paget’s disease of bone, osteoporosis, and postmenopausal osteoporosis. Treatment with salmon calcitonin results in the reduction of blood calcium levels as well as bone matrix resorption. Moreover, calcitonin from salmon has a higher efficacy per mg and a longer duration of effect than calcitonin from mammals.
The regulation of calcitonin secretion is complex and involves multiple factors, including calcium levels in the blood, gastrointestinal hormones, and nerve signals. Calcitonin levels are highest during rapid bone growth, such as in childhood, and tend to decline with age. Calcitonin has several physiological effects beyond its role in calcium and phosphate regulation. For instance, it has been found to reduce pain and inflammation and may play a role in regulating blood pressure and cardiovascular health. As a medication, calcitonin can be administered as a nasal spray, injection, or infusion. It is primarily used to treat conditions that involve excessive bone resorption, such as osteoporosis and Paget's disease. It may also reduce pain associated with bone fractures or other bone-related conditions.
Calcitonin Treatment Market Dynamics
The global calcitonin treatment market is primarily driven by the increasing prevalence of osteoporosis, a condition that occurs due to a lifelong deficiency of calcium. Poor calcium consumption increases the risk of fractures, early bone loss, and decreased bone density. Moreover, another major cause of osteoporosis is a decrease in estrogen levels in women at the time of menopause and lowered levels of testosterone in males. According to Bone Health 2022, osteoporotic fracture occurs every 3 seconds, which accounts for more than 8.9 million fractures globally. It is estimated that 200 million women globally have osteoporosis.
In recent years, there have been numerous advancements in calcitonin technology. These innovations include new methods for production, improvements in drug delivery systems, and an enhanced understanding of the mechanisms of action. Calcitonin is a hormone that plays a crucial role in regulating calcium levels in the body. With these advancements, new treatments and therapies are anticipated to emerge that may benefit patients suffering from conditions affecting calcium regulation.
Growing awareness about the benefits of calcitonin is a topic of great interest. Calcitonin has been shown to improve bone density and reduce the risk of fractures in many individuals. As more and more researchers and pharmaceutical companies come across the potential benefits of this treatment, the demand for calcitonin is projected to rise during the forecast years.
However, the presence of more effective drugs, such as bisphosphonates, for treating osteoporosis and hypercalcemia can limit the market revenue growth. Additionally, calcitonin is not recommended for long-term treatment due to its cancer-causing effects, which can reduce its usage. Moreover, other adverse effects include hypersensitivity reactions, hypocalcemia, nasal adverse reactions, and the formation of antibodies to calcitonin, majorly in postmenopausal women, restricting the global calcitonin treatment market revenue growth to some extent.
Calcitonin Treatment Market Ecosystem
The global calcitonin treatment market is analyzed from three perspectives: indications, route of administration, and region.
Calcitonin Treatment Market by Indications
[5675755]
Based on indications, the global calcitonin treatment market is segmented as Paget’s disease of bone, postmenopausal osteoporosis, and hypercalcemia.
The Paget’s disease segment dominates the global calcitonin treatment market with the largest revenue share of the market due to its high efficacy in treating the disease. Moreover, Food and Drug Administration (FDA) has approved calcitonin as a second-line treatment for Paget’s disease. Clinical studies have shown that it can reduce blood flow to damaged bones, correct neurologic impairments, and even improve Pagetic hearing loss. Additionally, the effective period of calcitonin is less than other treatment options, such as bisphosphonate therapy. This makes calcitonin therapy an effective treatment option for Paget’s disease.
Calcitonin is effective in treating postmenopausal osteoporosis. The FDA recently approved calcitonin for postmenopausal osteoporosis after the patient had five years of menopause. This hormone helps regulate calcium levels in the body, which can help prevent bone loss and promote bone growth. In addition, calcitonin has also been shown to reduce the risk of fractures in postmenopausal women.
Calcitonin has received FDA approval for use in treating hypercalcemia in emergencies. In hypercalcemia, calcitonin can resolve complications, such as disorientation, unconsciousness, dehydration, polyuria, kidney stones, nausea, constipation, pancreatitis, hypertension, and cardiac arrhythmias, offering relief to patients.
Calcitonin Treatment Market by Route of Administration
Based on the route of administration, the global calcitonin treatment market is segmented as parenteral and inhalation.
The inhalation segment dominates the global calcitonin treatment market with the largest market revenue share. This is majorly attributed to its direct delivery to the lungs, where it can be quickly absorbed into the bloodstream. Additionally, inhalation allows more efficient medication delivery than other methods, such as injection. Moreover, it provides more precise medication dosing, reducing drug wastage.
Calcitonin, in the form of injections, provides immediate access to the bloodstream, allowing for rapid and efficient medication absorption. This leads to faster symptom relief and improved patient outcomes.
Calcitonin Treatment Market by Region
Based on the region, the global calcitonin treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America accounted for the highest revenue share of the market in 2021, owing to the high prevalence of osteoporosis and associated disorders in the United States. Almost 10 million Americans have osteoporosis, and another 44 million have inadequate bone density, putting them at high risk. This indicates that half of all people over 50 are highly prone to osteoporosis. This prevalence rate is anticipated to increase during the forecast period due to the rising aging population, poor diets, and sedentary lifestyles. However, efforts are also being made to combat this epidemic through increased awareness about effective treatment options.
The calcitonin treatment market in Asia Pacific is expected to grow rapidly in the forecast period. This is attributed to the adoption of calcitonin for treating hypercalcemia and the development of new formulations of calcitonin that offer improved efficacy and convenience. The rising healthcare expenditure in the region is also driving the revenue growth of the Asia Pacific calcitonin treatment market.
Calcitonin Treatment Market Competitive Landscape
Several market players are adopting strategies, such as product launches, product approvals, patents, and events, to stay ahead of the competition. They are also using inorganic strategies, such as acquisition, partnership, and cooperation activities.
The prominent companies operating in the global calcitonin treatment market are:
Calcitonin Treatment Market Strategic Developments
Calcitonin, also known as thyrocalcitonin, is a linear polypeptide hormone produced by parafollicular cells in the thyroid glands of humans. Calcitonin decreases calcium and phosphate levels in the blood and stimulates bone growth.
Increasing technological advancements in calcitonin, the rising prevalence of osteoporosis, and growing awareness of the advantages of calcitonin are augmenting the market revenue growth.
Macleods Pharmaceuticals Pvt Ltd, Cipla Limited, Torrent Pharmaceuticals Ltd, and Endo International plc are among the top market players.
The global calcitonin treatment market is expected to register a revenue CAGR of 4.1% during the forecast period.
The Paget’s disease of bone segment dominates the global calcitonin treatment market.
Insights on financial performance are subject to the availability of information in the public domain